Follow The Filings

RVMD Revolution Medicines

Revolution Medicines earnings company data as of 10:08 AM ET 10/30

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS -2.38 — —
Rev $27.3M — —

Insider trades

Open-market buys and sales by RVMD's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RVMD insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $138M sold by 10 insiders under 10b5-1 plans
  1. Anthony Mancini See Remarks
    Planned sale
    $432K 2,310 shares at $186.99 5.5% of stake
    Traded Oct 26 Filed Oct 28
    ↗
  2. Alan B. Sandler Chief Development Officer
    Planned sale
    $1.3M 6,309 shares at $202.14 11% of stake
    Traded Sep 29 Filed Oct 1
    ↗
  3. Jeff Cislini SVP & General Counsel
    Planned sale
    $159K 765 shares at $207.32 1.5% of stake
    Traded Sep 25 Filed Sep 29
    ↗
  4. Anthony Mancini See Remarks
    Planned sale
    $743K 3,708 shares at $200.45 8.5% of stake
    Traded Sep 24–25 Filed Sep 28
    ↗
  5. Elizabeth M Anderson Director
    Planned sale
    $2M 10,143 shares at $193.04 70% of stake
    Traded Sep 22 Filed Sep 24
    ↗
  6. Anthony Mancini See Remarks
    Planned sale
    $347K 1,764 shares at $196.94 4.2% of stake
    Traded Sep 18 Filed Sep 22
    ↗
  7. Stephen Michael Kelsey See Remarks
    Planned sale
    $18.7M 92,531 shares at $202.36 24% of stake
    Traded Sep 11 Filed Sep 15
    ↗
  8. Anthony Mancini See Remarks
    Planned sale
    $3.2M 15,448 shares at $204.16 26% of stake
    Traded Sep 10 Filed Sep 14
    ↗
  9. Lorence H. Kim Director
    Planned sale
    $3.6M 17,090 shares at $209.82 100% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  10. Lorence H. Kim Director
    Planned sale
    $11.4M 56,000 shares at $203.24 77% of stake
    Traded Aug 31 Filed Sep 2
    ↗
  11. Jeff Cislini General Counsel
    Planned sale
    $11.9M 56,894 shares at $209.24 50% of stake
    Traded Aug 21 Filed Aug 25
    ↗
  12. Mark A Goldsmith See Remarks
    Planned sale
    $18M 86,000 shares at $209.20
    Traded Aug 21 Filed Aug 25
    ↗
  13. Sushil Patel Director
    Planned sale
    $1M 5,580 shares at $187.99 21% of stake
    Traded Jun 29 Filed Jul 1
    ↗
  14. Jack Anders CFO
    Planned sale
    $3.4M 20,000 shares at $168.33 14% of stake
    Traded Jun 24 Filed Jun 26
    ↗
  15. Margaret A Horn COO
    Planned sale
    $14.4M 90,000 shares at $160.16 37% of stake
    Traded Jun 15–17 Filed Jun 17
    ↗

Also filed in the last 12 months, not counted as buying or selling: 37 option exercises, 31 sales to cover taxes, 14 stock grants, and 6 gifts.

SEC filings

Recent issuer filings from EDGAR, 10 shown.

Filed Form Detail Links
8-K 2.03,8.01 Filing Doc
8-K 1.01,2.03 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,5.07 Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.